Suzuken Co (9987) AI Stock Analysis

• Market Cap: ¥295.86B
• Dividend Yield: 1.92%
• Average Volume (3M): 211.66K
• Price to Earnings (P/E): 11.5
• Beta (1Y): 0.50
• Revenue Growth: 1.67%
• EPS Growth: 31.66%
• Country: JP
• Employees: 13,086
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Distribution
• EPS (TTM): 197.25
• Shares Outstanding: 72,167,206
• 10 Day Avg. Volume: 175,130
• 30 Day Avg. Volume: 211,663
• PEG Ratio: 0.32
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,654.53
• Price Target Upside: 7.97% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ―

Suzuken Co's strong financial performance, highlighted by revenue growth and operational profitability, is the key strength. However, technical indicators suggest potential market underperformance, and cash flow volatility remains a concern. Valuation metrics indicate a fair price with reasonable income potential.

Suzuken Co Business Overview & Revenue Model

Company Description

Suzuken Co., Ltd. is a Japanese company primarily engaged in the distribution of pharmaceutical products. It operates in several sectors including pharmaceuticals, medical devices, and healthcare-related services. The company provides a wide range of products and services that cater to pharmacies, hospitals, and other medical institutions, ensuring the efficient distribution and availability of medical supplies across Japan.

How the Company Makes Money

Suzuken Co. makes money through its core business of pharmaceutical distribution. The company generates revenue by purchasing pharmaceutical products from manufacturers and distributing them to a network of pharmacies, hospitals, and healthcare providers. It earns margins on the distribution of these products. Additionally, Suzuken may engage in partnerships with pharmaceutical companies for exclusive distribution agreements, which can enhance its revenue streams. The company also offers logistics and healthcare-related services, contributing to its income by providing comprehensive solutions to its clients in the healthcare sector.

Suzuken Co Financial Statement Overview

Summary

Suzuken Co demonstrates strong revenue growth and profitability with robust margins and a debt-free balance sheet, indicating solid financial health. However, cash flow volatility suggests a need for better liquidity management.

Income Statement

Suzuken Co showcases a strong financial performance with a consistent increase in revenue over the years, indicating healthy growth. The TTM data reveals a gross profit margin of 8.02% and an impressive net profit margin of 1.42%. EBIT and EBITDA margins are also robust at 1.58% and 2.00% respectively, illustrating efficient cost management and operational profitability.

Balance Sheet

The balance sheet reflects solid financial health with zero debt, highlighting the company's strong financial position. The equity ratio stands at 31.72%, indicating a stable capital structure. The return on equity (ROE) is 8.27%, reflecting satisfactory shareholder returns, though there is room for improvement in increasing equity utilization.

Cash Flow

Cash flow analysis shows volatility, as demonstrated by fluctuations in free cash flow over the years. While operating cash flows have been positive, the TTM data indicates a lack of reported cash flow figures, which poses challenges in assessing current cash position and sustainability. Historical data suggests the need for better cash management strategies.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.41T	2.40T	2.39T	2.31T	2.23T	2.13T
Gross Profit	193.33B	192.23B	185.25B	179.69B	160.99B	157.84B
EBITDA	48.18B	62.38B	51.40B	39.48B	32.55B	22.92B
Net Income	34.19B	34.50B	29.02B	20.34B	14.39B	7.89B
Balance Sheet
Total Assets	1.30T	1.11T	1.23T	1.15T	1.14T	1.11T
Cash, Cash Equivalents and Short-Term Investments	205.53B	141.58B	242.11B	192.70B	201.46B	212.12B
Total Debt	0.00	0.00	0.00	1.80B	2.12B	2.28B
Total Liabilities	890.35B	706.41B	812.26B	734.57B	723.66B	696.51B
Stockholders Equity	413.63B	407.29B	416.31B	411.21B	417.69B	417.05B
Cash Flow
Free Cash Flow	0.00	-79.39B	71.58B	19.53B	-4.77B	7.74B
Operating Cash Flow	0.00	-65.08B	87.22B	37.27B	9.52B	15.60B
Investing Cash Flow	0.00	20.38B	10.35B	-46.36B	1.44B	-14.59B
Financing Cash Flow	0.00	-35.48B	-31.72B	-26.22B	-11.60B	-7.39B

Suzuken Co Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5237.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Neutral. The current price of 5237 is below the 20-day moving average (MA) of 5309.20, above the 50-day MA of 5228.52, and above the 200-day MA of 4944.98, indicating a neutral trend. The MACD of -7.52 indicates Positive momentum. The RSI at 43.42 is Neutral, neither overbought nor oversold. The STOCH value of 15.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9987.

Suzuken Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2875	76 Outperform	¥921.19B	14.29	13.14%	2.66%	3.80%	14.95%
7532	74 Outperform	¥2.98T	32.24	16.35%	1.00%	8.25%	6.55%
3391	71 Outperform	¥559.01B	25.27	4.93%	3.90%	4.63%	-47.30%
3349	70 Neutral	¥754.92B	25.53		0.70%	6.96%	18.31%
9987	65 Neutral	¥295.86B	11.47	8.32%	1.92%	1.67%	31.66%
3341	64 Neutral	$88.55B	65.86	2.35%	0.82%	5.94%	-45.43%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%

Suzuken Co Corporate Events

Suzuken Co. Revises Financial Forecast Upward Amid Strong Sales

Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.